An about 15% improvement in the tumor contrast enhancement and a 1.5-fold increase in the R2 values of the tumor periphery were seen in the group treated with FAP-targeted nanoprobes in comparison with the group with PSMA-targeted nanoprobes 119. Here, FOLH1 is linked to neoplasm.